Aadi Bioscience appoints Dornan as Chief Scientific Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2025
0mins
Appointment Announcement: Aadi Bioscience has appointed David Dornan, PhD as the new Chief Scientific Officer (CSO) of the company.
Expertise in Oncology: Dr. Dornan brings over 20 years of experience in oncology drug discovery and development, specializing in antibody-drug conjugates and targeted cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
